Tokyo Tape
Sign in
← Qol Holdings

Quarterly report · Q2

3034.TEDINET S100SA13
Period2023-04-01 → 2023-09-30
Filed2023-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥88.5bn2023-04-01 → 2023-09-30Cons.Net sales
Revenue¥170.0bn2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥82.5bn2022-04-01 → 2022-09-30Cons.Net sales
Operating income¥3.6bn2023-04-01 → 2023-09-30Cons.Operating income
Operating income¥4.0bn2022-04-01 → 2022-09-30Cons.Operating income
Ordinary income¥3.7bn2023-04-01 → 2023-09-30Cons.Ordinary income
Ordinary income¥10.1bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥4.2bn2022-04-01 → 2022-09-30Cons.Ordinary income
Profit before tax¥3.6bn2023-04-01 → 2023-09-30Cons.Income before income taxes
Profit before tax¥4.2bn2022-04-01 → 2022-09-30Cons.Income before income taxes
Net income (owners)¥1.9bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥5.7bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥2.4bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income¥1.9bn2023-04-01 → 2023-09-30Cons.Profit loss
Net income¥2.4bn2022-04-01 → 2022-09-30Cons.Profit loss
Total assets¥107.4bnat 2023-09-30Cons.Assets
Total assets¥101.9bnat 2023-03-31Cons.Assets
Total assets¥91.0bnat 2022-09-30Cons.Total assets (5-year summary)
Total liabilities¥57.1bnat 2023-09-30Cons.Liabilities
Total liabilities¥53.0bnat 2023-03-31Cons.Liabilities
Net assets / equity¥50.3bnat 2023-09-30Cons.Net assets
Net assets / equity¥48.9bnat 2023-03-31Cons.Net assets
Net assets / equity¥45.9bnat 2022-09-30Cons.Net assets (5-year summary)
Cash and deposits¥17.4bnat 2023-09-30Cons.Cash and deposits
Cash and deposits¥18.8bnat 2023-03-31Cons.Cash and deposits
Cash & equivalents¥17.3bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥18.6bnat 2023-03-31Cons.Cash and cash equivalents
Cash & equivalents¥14.3bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥16.5bnat 2022-03-31dCons.Cash and cash equivalents
Operating cash flow¥6.4bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥11.7bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥4.7bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥9.9bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥7.0bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥1.7bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Financing cash flow¥2.2bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥2.6bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥5.2bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥50.82023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥23.582023-07-01 → 2023-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥152.962022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥64.112022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥36.922022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio46.8%at 2023-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio47.9%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio50.4%at 2022-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 30
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥231m
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥231m
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥1.8bn
jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segmentrevenue2023-04-01 → 2023-09-30¥81.0bn
jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segmentrevenue external2023-04-01 → 2023-09-30¥81.0bn
jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥63m
jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segmentsegment profit2023-04-01 → 2023-09-30¥4.7bn
jpcrp040300-q2r_E03476-000Medical Relatedreportable segmentrevenue2023-04-01 → 2023-09-30¥7.7bn
jpcrp040300-q2r_E03476-000Medical Relatedreportable segmentrevenue external2023-04-01 → 2023-09-30¥7.6bn
jpcrp040300-q2r_E03476-000Medical Relatedreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥167m
jpcrp040300-q2r_E03476-000Medical Relatedreportable segmentsegment profit2023-04-01 → 2023-09-30¥658m
—segment totalrevenue2023-04-01 → 2023-09-30¥88.8bn
—segment totalrevenue external2023-04-01 → 2023-09-30¥88.5bn
—segment totalrevenue intersegment2023-04-01 → 2023-09-30¥231m
—segment totalsegment profit2023-04-01 → 2023-09-30¥5.4bn
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥181m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥181m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥1.7bn
jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segmentrevenue2022-04-01 → 2022-09-30¥75.6bn
jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segmentrevenue external2022-04-01 → 2022-09-30¥75.6bn
jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥58m
jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segmentsegment profit2022-04-01 → 2022-09-30¥5.1bn
jpcrp040300-q2r_E03476-000Medical Relatedreportable segmentrevenue2022-04-01 → 2022-09-30¥7.0bn
jpcrp040300-q2r_E03476-000Medical Relatedreportable segmentrevenue external2022-04-01 → 2022-09-30¥6.9bn
jpcrp040300-q2r_E03476-000Medical Relatedreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥123m
jpcrp040300-q2r_E03476-000Medical Relatedreportable segmentsegment profit2022-04-01 → 2022-09-30¥645m
—segment totalrevenue2022-04-01 → 2022-09-30¥82.6bn
—segment totalrevenue external2022-04-01 → 2022-09-30¥82.5bn
—segment totalrevenue intersegment2022-04-01 → 2022-09-30¥181m
—segment totalsegment profit2022-04-01 → 2022-09-30¥5.7bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 510
ItemContextValueUnit
Current portion of long term loans payablePrior1YearInstant8104000000JPY
Current portion of long term loans payableCurrentQuarterInstant6649000000JPY
Income taxes payablePrior1YearInstant1976000000JPY
Income taxes payableCurrentQuarterInstant1864000000JPY
Provision for bonusesPrior1YearInstant2310000000JPY
Provision for bonusesCurrentQuarterInstant2434000000JPY
Other clPrior1YearInstant3371000000JPY
Other clCurrentQuarterInstant3919000000JPY
Current liabilitiesPrior1YearInstant36330000000JPY
Current liabilitiesCurrentQuarterInstant43490000000JPY
Long term loans payablePrior1YearInstant14038000000JPY
Long term loans payableCurrentQuarterInstant10999000000JPY
Deferred tax liabilitiesPrior1YearInstant306000000JPY
Deferred tax liabilitiesCurrentQuarterInstant303000000JPY
Provision for directors retirement benefitsPrior1YearInstant34000000JPY
Provision for directors retirement benefitsCurrentQuarterInstant29000000JPY
Net defined benefit liabilityPrior1YearInstant829000000JPY
Net defined benefit liabilityCurrentQuarterInstant826000000JPY
Asset retirement obligations nclPrior1YearInstant1055000000JPY
Asset retirement obligations nclCurrentQuarterInstant1067000000JPY
Other nclPrior1YearInstant455000000JPY
Other nclCurrentQuarterInstant388000000JPY
Noncurrent liabilitiesPrior1YearInstant16719000000JPY
Noncurrent liabilitiesCurrentQuarterInstant13614000000JPY
LiabilitiesPrior1YearInstant53049000000JPY
LiabilitiesCurrentQuarterInstant57105000000JPY
Capital stockPrior1YearInstant5786000000JPY
Capital stockCurrentQuarterInstant5786000000JPY
Capital surplusPrior1YearInstant11276000000JPY
Capital surplusCurrentQuarterInstant11276000000JPY
Retained earningsPrior1YearInstant34355000000JPY
Retained earningsCurrentQuarterInstant35603000000JPY
Treasury stockPrior1YearInstant-2596000000JPY
Treasury stockCurrentQuarterInstant-2445000000JPY
Shareholders equityPrior1YearInstant48823000000JPY
Shareholders equityCurrentQuarterInstant50221000000JPY
Valuation difference on available for sale securitiesPrior1YearInstant-14000000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant-1000000JPY
Valuation and translation adjustmentsPrior1YearInstant-14000000JPY
Valuation and translation adjustmentsCurrentQuarterInstant-1000000JPY
Non controlling interestsPrior1YearInstant47000000JPY
Non controlling interestsCurrentQuarterInstant40000000JPY
Net assetsPrior1YearInstant48856000000JPY
Net assetsCurrentQuarterInstant50260000000JPY
Liabilities and net assetsPrior1YearInstant101905000000JPY
Liabilities and net assetsCurrentQuarterInstant107365000000JPY
Net salesPrior1YTDDuration82459000000JPY
Net salesCurrentYTDDuration88540000000JPY
Cost of salesPrior1YTDDuration71602000000JPY
Cost of salesCurrentYTDDuration77508000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2023-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass